First, osimertinib has been conditionally covered by national reimbursement in Taiwan since April 2020, and the benefits coverage are applicable only to first-line therapy in advanced NSCLC patients with EGFR exon 19 deletion mutation and brain metastasis and late-line therapy for T790M-mutated NSCLC patients experiencing acquired resistance to prior 1st- and 2nd-generation EGFR-TKI therapies [37]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.